InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-29.5%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Silberman David, Chief Financial Officer. Officer active across 1 company, notably Oramed Pharmaceuticals INC.. In total, 8 filings have been published. History available since 1 September 2021. The latest transaction was disclosed on 1 September 2021 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations8 total
136,500 sharesCommon StockSEC:0001209191-24-001146:0
24,500 sharesCommon StockSEC:0001209191-23-033141:0
97,500 sharesCommon StockSEC:0001209191-23-024936:0
39,000 sharesCommon StockSEC:0001209191-22-043765:0
19,000 sharesCommon StockSEC:0001213900-22-000805:0
19,000 sharesCommon StockSEC:0001213900-22-000805
50,000 shares0Common StockSEC:0001213900-21-046413:0
50,000 shares0Common StockSEC:0001213900-21-046413
8 of 8 declarations
About Silberman David
David Silberman is the Chief Financial Officer at ORAMED PHARMACEUTICALS INC. He is responsible for the financial management of the company, overseeing financial planning and analysis. Silberman plays a key role in financial strategy and decision-making that influences ORAMED's performance.
